Alterola Biotech Cash Flow From Operations vs. Price To Book
| ABTI Stock | USD 0.01 0 32.76% |
For Alterola Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alterola Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alterola Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alterola Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alterola Biotech over time as well as its relative position and ranking within its peers.
Alterola |
Alterola Biotech Price To Book vs. Cash Flow From Operations Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Alterola Biotech's current stock value. Our valuation model uses many indicators to compare Alterola Biotech value to that of its competitors to determine the firm's financial worth. Alterola Biotech is rated third in cash flow from operations category among its peers. It is number one stock in price to book category among its peers . The ratio of Cash Flow From Operations to Price To Book for Alterola Biotech is about 7,050 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Alterola Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alterola Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Alterola Price To Book vs. Cash Flow From Operations
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Alterola Biotech |
| = | 44.34 K |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Alterola Biotech |
| = | 6.29 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Alterola Price To Book Comparison
Alterola Biotech is currently under evaluation in price to book category among its peers.
Alterola Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Alterola Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alterola Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Alterola Biotech's change in net profit over the period of time. It can combine multiple indicators of Alterola Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States.
Alterola Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Alterola Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alterola Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alterola Biotech's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Alterola Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Alterola Biotech position
In addition to having Alterola Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banking Thematic Idea Now
Banking
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banking theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banking Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Alterola Pink Sheet
To fully project Alterola Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alterola Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alterola Biotech's income statement, its balance sheet, and the statement of cash flows.